Indivior PLC(INDV) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenue of $856 million for SUBLOCADE, a 13% increase compared to 2024, and total net revenue of $1.24 billion, representing a 4% increase year-over-year [5][19] - Adjusted EBITDA grew 20% year-over-year to $428 million in 2025, with notable margin improvement [5][24] - Operating expenses are projected to not exceed $450 million in 2026 [5] Business Line Data and Key Metrics Changes - SUBLOCADE dispense volume grew 12% year-over-year in Q4 and 6% compared to Q3, with new patient starts up 25% year-over-year [12][20] - Total SUBLOCADE net revenue for Q4 was $252 million, a 30% increase year-over-year [20] - SUBOXONE Film net revenue benefited from continued generic price stability, with Q4 net revenue including a gross benefit of $23 million [21] Market Data and Key Metrics Changes - The long-acting injectables (LAIs) category saw growth approaching 18% in Q4 2025 [40][44] - The company reported stabilization of SUBLOCADE's market share in the mid-70s [13][34] Company Strategy and Development Direction - The company is executing phase II of the Indivior Action Agenda, focusing on accelerating SUBLOCADE dispense unit growth and net revenue throughout 2026 [8][28] - A new $400 million share repurchase program has been authorized to return value to shareholders [7][27] - The company aims to strategically deploy capital to create long-term value, focusing on managing debt and evaluating business development opportunities [10][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's momentum and the potential for SUBLOCADE, emphasizing that long-acting injectables remain underutilized [9][34] - The company expects to deliver SUBLOCADE dispense unit growth in the mid-teens in 2026, an acceleration from the 7% growth achieved in 2025 [9][25] - Management is optimistic about the engagement from the direct-to-consumer campaign launched in October 2025, which has shown early indicators of success [16][17] Other Important Information - The company eliminated a significant future liability by paying the outstanding $295 million obligation related to a legacy DOJ matter [6][26] - The company ended 2025 with gross cash and investments of $222 million, with net leverage below one time [26] Q&A Session Summary Question: Thoughts on LAI buprenorphine modalities penetration and market share - Management believes there is significant opportunity for LAI penetration, currently at 9%, with potential growth to 20%-30% based on market research [33][34] Question: Guidance assumptions for LAI market growth and share in 2026 - Management expects mid-teen SUBLOCADE growth and continued stabilization of market share [41][42] Question: Medicaid funding landscape impact on SUBLOCADE - Management is optimistic about Medicaid support and believes there is substantial growth opportunity for SUBLOCADE regardless of Medicaid funding fluctuations [51][52] Question: Shape of SG&A in 2026 and DTC spending - Management indicated that DTC spending is a priority and will be maintained for a multi-year period to drive long-acting injectable penetration [51] Question: Contribution from the criminal justice system to SUBLOCADE guidance - Management sees the criminal justice segment as a strong opportunity for growth, contributing to the overall guidance for mid-teens growth [67] Question: Expectations for SUBLOCADE ex U.S. revenues - Management anticipates relatively flat year-over-year revenues for SUBLOCADE outside the U.S., with growth in some regions offset by declines in others [71]